GB201423361D0 - Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides - Google Patents

Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides

Info

Publication number
GB201423361D0
GB201423361D0 GBGB1423361.3A GB201423361A GB201423361D0 GB 201423361 D0 GB201423361 D0 GB 201423361D0 GB 201423361 A GB201423361 A GB 201423361A GB 201423361 D0 GB201423361 D0 GB 201423361D0
Authority
GB
United Kingdom
Prior art keywords
absolute quantification
naturally processed
cancer peptides
restricted cancer
processed hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1423361.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1423361.3A priority Critical patent/GB201423361D0/en
Publication of GB201423361D0 publication Critical patent/GB201423361D0/en
Priority to BR112017008212-8A priority patent/BR112017008212B1/pt
Priority to MA41287A priority patent/MA41287B1/fr
Priority to MDE20170252T priority patent/MD3241026T2/ro
Priority to CA2972306A priority patent/CA2972306C/en
Priority to HUE15822924A priority patent/HUE054455T2/hu
Priority to CR20170297A priority patent/CR20170297A/es
Priority to PE2017000941A priority patent/PE20171136A1/es
Priority to MX2017008722A priority patent/MX383806B/es
Priority to SG11201703841VA priority patent/SG11201703841VA/en
Priority to JP2017521534A priority patent/JP6735741B2/ja
Priority to LTEP15822924.5T priority patent/LT3241026T/lt
Priority to SG10201913988XA priority patent/SG10201913988XA/en
Priority to EA201791148A priority patent/EA036328B1/ru
Priority to EP15822924.5A priority patent/EP3241026B1/en
Priority to TW104142137A priority patent/TWI632370B/zh
Priority to PCT/EP2015/079873 priority patent/WO2016107740A1/en
Priority to KR1020177017911A priority patent/KR102336968B1/ko
Priority to US14/969,423 priority patent/US10545154B2/en
Priority to MYPI2017700825A priority patent/MY190199A/en
Priority to CN201580063711.6A priority patent/CN107003322B/zh
Priority to SI201531612T priority patent/SI3241026T1/sl
Priority to DK15822924.5T priority patent/DK3241026T3/da
Priority to ES15822924T priority patent/ES2871035T3/es
Priority to UAA201701977A priority patent/UA122774C2/uk
Priority to PT158229245T priority patent/PT3241026T/pt
Priority to AU2015373584A priority patent/AU2015373584B2/en
Priority to PL15822924T priority patent/PL3241026T3/pl
Priority to RS20210672A priority patent/RS61914B1/sr
Priority to MA40137A priority patent/MA40137B1/fr
Priority to HRP20210811TT priority patent/HRP20210811T1/hr
Priority to IL250982A priority patent/IL250982B/en
Priority to ZA2017/01646A priority patent/ZA201701646B/en
Priority to PH12017500483A priority patent/PH12017500483A1/en
Priority to CL2017001071A priority patent/CL2017001071A1/es
Priority to CONC2017/0004543A priority patent/CO2017004543A2/es
Priority to US16/685,765 priority patent/US11988669B2/en
Priority to CY20211100514T priority patent/CY1124223T1/el
Priority to US18/638,970 priority patent/US20240280583A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
GBGB1423361.3A 2014-12-30 2014-12-30 Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides Ceased GB201423361D0 (en)

Priority Applications (39)

Application Number Priority Date Filing Date Title
GBGB1423361.3A GB201423361D0 (en) 2014-12-30 2014-12-30 Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
HRP20210811TT HRP20210811T1 (hr) 2014-12-30 2015-12-15 Metoda apsolutne kvantifikacije prirodno prerađenih peptida raka ograničenih na hla
US14/969,423 US10545154B2 (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed HLA-restricted cancer peptides
MYPI2017700825A MY190199A (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
MDE20170252T MD3241026T2 (ro) 2014-12-30 2015-12-15 Metodă pentru cuantificarea absolută a peptidelor de cancer restricționate de HLA procesate natural
CA2972306A CA2972306C (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
HUE15822924A HUE054455T2 (hu) 2014-12-30 2015-12-15 Módszer a természetes módon feldolgozott, HLA-korlátozott rákpeptidek abszolút mennyiségi meghatározására
CR20170297A CR20170297A (es) 2014-12-30 2015-12-15 Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma natural
PE2017000941A PE20171136A1 (es) 2014-12-30 2015-12-15 Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma natural
MX2017008722A MX383806B (es) 2014-12-30 2015-12-15 Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma natural.
SG11201703841VA SG11201703841VA (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
JP2017521534A JP6735741B2 (ja) 2014-12-30 2015-12-15 自然にプロセスされたｈｌａ拘束性がんペプチドを絶対的定量化する方法
LTEP15822924.5T LT3241026T (lt) 2014-12-30 2015-12-15 Natūraliai apdorotų vėžio peptidų su pašalintais hla aleliais absoliučiojo kiekio nustatymo metodas
SG10201913988XA SG10201913988XA (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
EA201791148A EA036328B1 (ru) 2014-12-30 2015-12-15 Способ определения абсолютных количеств hla-рестриктированных раковых пептидов, образовавшихся в результате естественного процессинга
EP15822924.5A EP3241026B1 (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
TW104142137A TWI632370B (zh) 2014-12-30 2015-12-15 天然加工的ｈｌａ限制性癌胜肽絕對定量方法
PCT/EP2015/079873 WO2016107740A1 (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
MA41287A MA41287B1 (fr) 2014-12-30 2015-12-15 Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement
BR112017008212-8A BR112017008212B1 (pt) 2014-12-30 2015-12-15 Método de quantificação absoluta de pelo menos um peptídeo ligante de mhc em uma célula
CN201580063711.6A CN107003322B (zh) 2014-12-30 2015-12-15 天然加工的hla限制性癌肽绝对定量方法
KR1020177017911A KR102336968B1 (ko) 2014-12-30 2015-12-15 자연적으로 처리된 hla-제한 암 펩티드의 절대 정량 방법
UAA201701977A UA122774C2 (uk) 2014-12-30 2015-12-15 Спосіб визначення абсолютних кількостей hla-рестриктованих ракових пептидів, що утворюються в результаті природного процесингу
DK15822924.5T DK3241026T3 (da) 2014-12-30 2015-12-15 Fremgangsmåde til absolut kvantificering af naturligt forarbejdede hla-begrænsede cancerpeptider
ES15822924T ES2871035T3 (es) 2014-12-30 2015-12-15 Método para la cuantificación absoluta de péptidos cancerosos restringidos a HLA que son procesados de forma natural
SI201531612T SI3241026T1 (sl) 2014-12-30 2015-12-15 Postopek absolutne kvantifikacije naravno obdelanih peptidov raka, omejenih s HLA
PT158229245T PT3241026T (pt) 2014-12-30 2015-12-15 Método para quantificação absoluta de péptidos cancerosos naturalmente processados e restritos por hla
AU2015373584A AU2015373584B2 (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
PL15822924T PL3241026T3 (pl) 2014-12-30 2015-12-15 Metoda bezwzględnego określenia ilościowego naturalnie przetwarzanych ograniczonych do hla peptydów nowotworowych
RS20210672A RS61914B1 (sr) 2014-12-30 2015-12-15 Metod za apsolutnu kvantifikaciju prirodno obrađenih hla- restrikovanih peptida malignih tumora
MA40137A MA40137B1 (fr) 2014-12-30 2015-12-15 Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement
ZA2017/01646A ZA201701646B (en) 2014-12-30 2017-03-07 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
IL250982A IL250982B (en) 2014-12-30 2017-03-07 An absolute method for the quantification of restricted, naturally processed cancer peptides
PH12017500483A PH12017500483A1 (en) 2014-12-30 2017-03-14 Method for the absolute qualification of naturally processed hla-restircted cancer peptides
CL2017001071A CL2017001071A1 (es) 2014-12-30 2017-04-28 Método para la cuantificación absoluta de péptidos cancerígenos hla-restringidos procesados naturalmente
CONC2017/0004543A CO2017004543A2 (es) 2014-12-30 2017-05-05 Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma natural
US16/685,765 US11988669B2 (en) 2014-12-30 2019-11-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
CY20211100514T CY1124223T1 (el) 2014-12-30 2021-06-10 Μεθοδος για τον ακριβη ποσοτικο προσδιορισμο των φυσικα επεξεργασμενων περιορισμενων me hla καρκινικων πεπτιδιων
US18/638,970 US20240280583A1 (en) 2014-12-30 2024-04-18 Method for the absolute quantification of naturally processed hla-restricted cancer peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1423361.3A GB201423361D0 (en) 2014-12-30 2014-12-30 Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides

Publications (1)

Publication Number Publication Date
GB201423361D0 true GB201423361D0 (en) 2015-02-11

Family

ID=52471641

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1423361.3A Ceased GB201423361D0 (en) 2014-12-30 2014-12-30 Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides

Country Status (35)

Country Link
US (3) US10545154B2 (cg-RX-API-DMAC7.html)
EP (1) EP3241026B1 (cg-RX-API-DMAC7.html)
JP (1) JP6735741B2 (cg-RX-API-DMAC7.html)
KR (1) KR102336968B1 (cg-RX-API-DMAC7.html)
CN (1) CN107003322B (cg-RX-API-DMAC7.html)
AU (1) AU2015373584B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017008212B1 (cg-RX-API-DMAC7.html)
CA (1) CA2972306C (cg-RX-API-DMAC7.html)
CL (1) CL2017001071A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017004543A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170297A (cg-RX-API-DMAC7.html)
CY (1) CY1124223T1 (cg-RX-API-DMAC7.html)
DK (1) DK3241026T3 (cg-RX-API-DMAC7.html)
EA (1) EA036328B1 (cg-RX-API-DMAC7.html)
ES (1) ES2871035T3 (cg-RX-API-DMAC7.html)
GB (1) GB201423361D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20210811T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054455T2 (cg-RX-API-DMAC7.html)
IL (1) IL250982B (cg-RX-API-DMAC7.html)
LT (1) LT3241026T (cg-RX-API-DMAC7.html)
MA (2) MA40137B1 (cg-RX-API-DMAC7.html)
MD (1) MD3241026T2 (cg-RX-API-DMAC7.html)
MX (1) MX383806B (cg-RX-API-DMAC7.html)
MY (1) MY190199A (cg-RX-API-DMAC7.html)
PE (1) PE20171136A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500483A1 (cg-RX-API-DMAC7.html)
PL (1) PL3241026T3 (cg-RX-API-DMAC7.html)
PT (1) PT3241026T (cg-RX-API-DMAC7.html)
RS (1) RS61914B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201703841VA (cg-RX-API-DMAC7.html)
SI (1) SI3241026T1 (cg-RX-API-DMAC7.html)
TW (1) TWI632370B (cg-RX-API-DMAC7.html)
UA (1) UA122774C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016107740A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701646B (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
KR20240151873A (ko) * 2015-03-17 2024-10-18 이매틱스 바이오테크놀로지스 게엠베하 췌장암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
NZ754222A (en) 2016-12-08 2022-02-25 Immatics Biotechnologies Gmbh T cell receptors with improved pairing
RS61817B1 (sr) 2017-07-14 2021-06-30 Immatics Biotechnologies Gmbh Poboljšani polipeptidni molekul sa dvojnom specifičnošću
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
WO2019157298A1 (en) * 2018-02-09 2019-08-15 Immatics US, Inc. Methods for manufacturing t cells
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
KR102731127B1 (ko) 2018-09-05 2024-11-18 에스케이하이닉스 주식회사 메모리 컨트롤러 및 이를 포함하는 메모리 시스템
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
TWI872076B (zh) 2019-05-27 2025-02-11 美商英麥提克斯股份有限公司 病毒載體及其在授受性細胞療法之應用
WO2020245326A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN114568032A (zh) 2019-08-09 2022-05-31 伊玛提克斯美国公司 肽质谱片段化预测方法
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
WO2022147029A2 (en) 2020-12-31 2022-07-07 Immatics US, Inc. Cd8 polypeptides, compositions, and methods of using thereof
US20220372165A1 (en) 2021-05-05 2022-11-24 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CA3217739A1 (en) 2021-05-05 2022-11-10 Sebastian Bunk Bma031 antigen binding polypeptides
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
MX2024001179A (es) 2021-07-27 2024-02-27 Immatics Biotechnologies Gmbh Proteinas de union a antigenos que se unen especificamente a ct45.
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス，アイエヌシー． 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択
WO2023044488A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230190807A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Tcr compounds, compositions, and methods of treating
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
WO2025008513A1 (en) 2023-07-05 2025-01-09 Immatics Biotechnologies Gmbh A method of identifying mhc-binding proteins and interacting peptides in a sample
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025021968A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Antigen binding proteins against mageb2
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025125535A1 (en) 2023-12-13 2025-06-19 Immatics Biotechnologies Gmbh Differential population-scale immunopeptidomics
WO2025125536A1 (en) 2023-12-13 2025-06-19 Immatics Biotechnologies Gmbh Absolute copy number prediction of mhc-presented peptides by relative quantitative measurement
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
WO2025233420A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use of anti-cancer molecules

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025576A2 (en) 2001-09-14 2003-03-27 Xzillion Gmbh & Co. Kg Mass labels
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US6644103B1 (en) 2002-10-24 2003-11-11 Simmonds Precision Products, Inc. Method and apparatus for detecting a dry/wet state of a thermistor bead
JPWO2004042401A1 (ja) * 2002-11-08 2006-03-09 高橋　弘 癌細胞の検査方法及びそのための試薬
WO2005076009A2 (en) 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
JP2008043332A (ja) * 2006-08-17 2008-02-28 Panomics Inc 組織スライドからの核酸定量
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2697655A2 (en) 2011-04-15 2014-02-19 Micromass UK Limited Method and apparatus for the analysis of biological samples
WO2012178030A2 (en) 2011-06-24 2012-12-27 Applied Isotope Technologies, Inc. Accurate measurement of glutathione for disease diagnosis and drug metabolite screening
US10077171B2 (en) * 2012-10-17 2018-09-18 Grant C. Chustz Safety barrier for vehicles and cranes
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
EP4219543A1 (en) * 2017-11-06 2023-08-02 Immatics Biotechnologies GmbH Novel engineered t cell receptors and immune therapy using the same

Also Published As

Publication number Publication date
MA41287A (fr) 2017-11-08
CA2972306C (en) 2021-02-16
DK3241026T3 (da) 2021-05-10
KR20170099914A (ko) 2017-09-01
MA40137B1 (fr) 2019-05-31
EP3241026A1 (en) 2017-11-08
US11988669B2 (en) 2024-05-21
JP6735741B2 (ja) 2020-08-05
PH12017500483A1 (en) 2017-08-07
HUE054455T2 (hu) 2021-09-28
CN107003322B (zh) 2019-08-30
PE20171136A1 (es) 2017-08-09
MY190199A (en) 2022-04-04
EP3241026B1 (en) 2021-04-14
TW201631320A (zh) 2016-09-01
CL2017001071A1 (es) 2017-12-22
CR20170297A (es) 2017-10-19
AU2015373584B2 (en) 2022-02-24
PL3241026T3 (pl) 2021-10-25
JP2018500004A (ja) 2018-01-11
MA40137A1 (fr) 2018-03-30
US20200103408A1 (en) 2020-04-02
ZA201701646B (en) 2018-05-30
RS61914B1 (sr) 2021-06-30
SG11201703841VA (en) 2017-07-28
KR102336968B1 (ko) 2021-12-08
PT3241026T (pt) 2021-05-25
EA036328B1 (ru) 2020-10-27
SI3241026T1 (sl) 2021-08-31
MX2017008722A (es) 2017-10-18
UA122774C2 (uk) 2021-01-06
US10545154B2 (en) 2020-01-28
US20240280583A1 (en) 2024-08-22
EA201791148A1 (ru) 2017-11-30
US20160187351A1 (en) 2016-06-30
IL250982B (en) 2020-08-31
ES2871035T3 (es) 2021-10-28
LT3241026T (lt) 2021-05-25
WO2016107740A1 (en) 2016-07-07
CY1124223T1 (el) 2022-05-27
SG10201913988XA (en) 2020-03-30
HRP20210811T1 (hr) 2021-09-03
IL250982A0 (en) 2017-04-30
MD3241026T2 (ro) 2021-07-31
MX383806B (es) 2025-03-14
MA41287B1 (fr) 2021-07-29
TWI632370B (zh) 2018-08-11
BR112017008212B1 (pt) 2023-11-28
CO2017004543A2 (es) 2017-09-29
AU2015373584A1 (en) 2017-04-20
CA2972306A1 (en) 2016-07-07
BR112017008212A2 (pt) 2017-12-26
CN107003322A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
ZA201701646B (en) Method for the absolute quantification of naturally processed hla-restricted cancer peptides
GB201616590D0 (en) Method
GB201609221D0 (en) Method
PT3368683T (pt) Método para a quantificação de pd-l1
GB201611953D0 (en) Method
GB201602394D0 (en) Method
GB2547966B (en) De-aliased source separation method
HUP1400114A2 (en) Method for the production of peptides
GB2547965B (en) Source separation method
IL248283B (en) A method for the synthesis of cloprabine
IL259107B (en) A method to remove camouflage from an object
GB201506117D0 (en) Method for chromatography
GB201506113D0 (en) Method for chromatography
IL257514A (en) A method for detecting cancer
IL258898A (en) Methods for the synthesis of 2-alkyl-4-trifluoromethyl-3-alkylsulfonylbenzoic acids
PL3336368T3 (pl) Sposób bezobrotowego łączenia dwóch elementów
GB201601120D0 (en) Eye-testing method
GB201604809D0 (en) Method for detecting cancer
GB201522150D0 (en) Saftey Apparatus
GB201604204D0 (en) Method
SG11201707200PA (en) Method for shape classification of an object
GB201601086D0 (en) Method
GB201601046D0 (en) Method
GB201601044D0 (en) Method
GB201600751D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)